TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Phosphorus excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Net absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: total cost per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Enamel caries incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean total one‐year costs per patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Physical dating violence victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Emotional dating violence victimization
Endpoint domain: Adverse events/effects
Primary endpoint: Emotional dating violence perpetration
Endpoint domain: Adverse events/effects
Primary endpoint: First-attempt success rates for peripheral venous access
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Debris removal effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean pain score during anaesthetic administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Any target vessel revascularization (TVR) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: ELF index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Mean wrinkle score decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin elasticity increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction in TBARS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in dROMs levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in endothelial function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the 30-min FEV(1) time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Carer mental health status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Preventing laboratory-confirmed clinical influenza
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preventing laboratory-confirmed illnesses with fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Preventing all influenza infections
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Left Ventricular Wall Motion Score Index (LV WMSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mYPAS scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eosinophil count in postallergen nasal lavage fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Allergen-induced change in nasal potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in nasal albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of GWVIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean HGF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Perceived effectiveness of music therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: A1C changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: DC yield per cell
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: total-body dose (Gy)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cytotoxic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean overall history rating of excellent/good
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean overall physical examination rating of excellent/good
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of carious lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in NPQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VAS scores at work and sports
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mayo 12 points elbow scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to work and sports postoperatively
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Quantity of detectable amylase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantity of detectable albumin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in risk of death from any cause
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of women with risks addressed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: feasibility of establishing creative classes for women with symptoms of PND
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Overall cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Outpatient cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Quality of life rating scale scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Sternal dehiscence rates
Endpoint domain: Adverse events/effects
Primary endpoint: Mean JOA score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in diameter of the spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of CI-AKI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: End-of-treatment RECIST response (CR+PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average pain reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median oral opioid consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: RBV dose maintenance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hemoglobin (Hb) increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nine-month survival
Endpoint domain: Mortality/survival
Primary endpoint: Tramadol consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compulsory readmissions to psychiatry
Endpoint domain: Adverse events/effects
Primary endpoint: Number of compulsory readmissions per patient
Endpoint domain: Adverse events/effects
Primary endpoint: Duration of involuntary episodes
Endpoint domain: Adverse events/effects
Primary endpoint: Improved sensitivity for correctly identifying a lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved positive predictive value (PPV) for correctly identifying a lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically important improvement on the CTQ‐Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Norepinephrine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Arterial lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: venous filling time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing physiology improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BLS performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of PAI, ANP, ET in hypertensive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of t-PA, IS in hypertensive patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: International Prostatic Symptom Score (IPSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post Void Residual Urine (PVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved lesion conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in PEA levels from baseline to 24 hours posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in stress from baseline to day 5
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reduction in 5-HIAA and 5-HT levels at 30 minutes and 24 hours posttreatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of gastrointestinal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Hepatocyte growth factor-positive Kupffer and Ito cells density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive staining in chronic hepatitis specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunohistochemical detection of hepatocyte growth factor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of all-cause mortality, stroke, or myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Rates of remission (HRSD < 7)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Side-effect intensity
Endpoint domain: Adverse events/effects
Primary endpoint: ON flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PP (Pulse Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean improvement in self-rated health (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: percentage of success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: investigator‐assessed erythema and scaling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patients' assessed pruritus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency distribution of d3/fl-GHR genotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of colonization
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter related local infection (CRI)
Endpoint domain: Adverse events/effects
Primary endpoint: Catheter related systemic infection (CR-SI)
Endpoint domain: Adverse events/effects
Primary endpoint: VAS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRTEE
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QDASH
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-reactive protein (CRP) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin 18 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in mean IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction in spell frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in use of rescue medication
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in psychological measures reflecting internal locus of control
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ferritin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of gastrointestinal side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Number of days without seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in overall score from pre-education to early posteducation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: plasma levels of TNF‐α
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma levels of CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Healthcare time used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Knowledge acquisition and self-care treatment adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: metered dose inhaler technique score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success rate of ILV vs NPPV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: HDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: LDL peak diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global processing improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Faster text reading speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative cognitive dysfunction (POCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: GFR improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in CHD events
Endpoint domain: Mortality/survival
Primary endpoint: ACR70 response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: glycated haemoglobin (HbA1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: low density lipoprotein cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Recurrence of depressive episodes
Endpoint domain: Mortality/survival
Primary endpoint: Knowledge increase about health research studies
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nocturia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total O'Leary reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability (Foral)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic extraction (EH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral clearance (CL/F)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swallowing function improvement (MASA score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence rate of infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: overall non‐infectious complications
Endpoint domain: Adverse events/effects
Primary endpoint: IWSRI mean scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total posterior contacts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Avoidance of operative intervention
Endpoint domain: Mortality/survival
Primary endpoint: Decreases in neurological symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Decreases in back pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of phone interviews for PTSD and MDD assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of stress response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LID deterioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: TRAP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TBARS levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Prediction of neoplasia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Pain level reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinically important skin complications
Endpoint domain: Adverse events/effects
Primary endpoint: clinically important pulmonary complications
Endpoint domain: Adverse events/effects
Primary endpoint: Mean intravascular fluid loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MDI scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of harvested lymph nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Proportion of harvested small nodes (< 5 mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Mean harvest time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Local recurrence rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Isolated nodal failure (INF) rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma paracetamol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve (AUC) of paracetamol concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of wound disruption
Endpoint domain: Adverse events/effects
Primary endpoint: Days with sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental health after 6 months
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: incremental cost per quality-adjusted life years
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Prevalence of students who did not eat fruit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in being overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cancer behavioral risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall cardiovascular risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time to worsen by at least one Expanded Disability Status Scale point
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 3-year risk of worsening disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduced relapse rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hip fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Average reduction of scoliosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary excretion of CTX-II
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: surface erosion of knee articular cartilage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of life index improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Resolution of complications from adjacent organs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant follow-up completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Loss of pancreatic enzyme secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Normalization of ALT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: HBV DNA clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: compliance rates
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in serum low-density lipoprotein cholesterol (LDL-C) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in lipid index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in macrophage grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with one or more VF/VT episodes after ROSC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes